Myriad Genetics, Inc. signs asset purchase agreement with LabCorp
Myriad Genetics will sell assets to LabCorp as part of a strategic restructuring of its genetic testing business. The deal is valued at approximately $900 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed